Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Novel treatment paradigms for AML at ASH 2021

Daniel Pollyea • 10 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia

Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, discusses highlights during the symposium on the topic of evidence-based guidance on current paradigms and new therapeutic approaches in acute myeloid leukemia (AML). He emphasizes how much progress has been recently made within the treatment landscape, as well as the development of targeted therapies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Daniel Pollyea

County-level analysis exploring environmental contributors to myeloid malignancies in Colorado
0:49
County-level analysis exploring environmental contributors to myeloid malignancies in Colorado
Daniel Pollyea • 5 Dec 2025
Venetoclax resistance in AML
10:35
Venetoclax resistance in AML
Curtis Lachowiez et al. • 17 Mar 2025
Venetoclax plus azacitidine for newly diagnosed younger AML
1:29
Venetoclax plus azacitidine for newly diagnosed younger AML
Daniel Pollyea • 6 Dec 2024
Omacetaxine and azacitidine for newly diagnosed patients with MDS and excess blasts
1:20
Omacetaxine and azacitidine for newly diagnosed patients with MDS and excess blasts
Daniel Pollyea • 6 Dec 2024

Related Videos

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
Managing FLT3-ITD mutant AML in remission
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
The content of VJHemOnc is intended for healthcare professionals